Evaluation of the Efficacy of Different Doses of rt-PA Intravenous Thrombolysis Combined with Rosuvastatin in the Emergency Treatment of Ischemic Stroke
LI Chunxia, MI Jingjing
Yulin Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Yulin 719000, China
Abstract：Objective: To analyze the efficacy of combined application of intravenous thrombolysis with different doses of recombinant tissue plasminogen activator (rt-PA) and rosuvastatin in the ischemic stroke emergency treatment. Methods: Two hundred and ten patients with ischemic stroke in the hospital were enrolled between July 2021 and July 2024, and were divided into low-dose group (n=108, 0.6mg/kg) and high-dose group (n=102, 0.9mg/kg) according to the dose of rt-PA. The efficacy in the two groups was evaluated. The coagulation indexes, neurological function and activities of daily living were compared between both groups before and after treatment, and the safety was assessed. Results: The total effective rate in the low-dose group with 90.74% was not statistically different from 83.33% in the high-dose group (P>0.05). At 7 days after treatment, the fibrinogen (Fib) level in the two groups was reduced while the D-dimer (D-D) level was enhanced (P<0.05). There was no statistical significance in the difference value of Fib level before and after treatment between the low-dose group and the high-dose group (P>0.05), but the difference value of D-D level before and after treatment in the low-dose group was higher in comparison with the high-dose group (P<0.05). A statistical difference was exhibited in the National Institutes of Health Stroke Scale (NIHSS) score at different time points (P<0.05), and the NIHSS score revealed no statistical difference between the two groups (P>0.05), and the interaction effect between time-point and group was not statistically significant (P>0.05). The barthel index was statistically different at different time points (P<0.05). The barthel index revealed no statistical difference between groups (P>0.05), and no statistical significance was found in the interaction effect between time-point and group (P>0.05). The incidence rates of complications were lower in the low-dose group compared to the high-dose group (P<0.05). Conclusion: The efficacy of low-dose rt-PA intravenous thrombolysis combined with rosuvastatin and its effects on coagulation function, neurological function and activities of daily living in the emergency treatment of ischemic stroke are comparable to those of high-dose group. However, compared with high-dose rt-PA, low-dose rt-PA intravenous thrombolysis has higher safety.
李春霞, 米晶晶. 不同剂量rt-PA静脉溶栓联合瑞舒伐他汀急救缺血性脑卒中的疗效评估[J]. 河北医学, 2025, 31(8): 1396-1401.
LI Chunxia, MI Jingjing. Evaluation of the Efficacy of Different Doses of rt-PA Intravenous Thrombolysis Combined with Rosuvastatin in the Emergency Treatment of Ischemic Stroke. HeBei Med, 2025, 31(8): 1396-1401.
[1] Chen H,Lee JS,Michel P,et al.Endovascular stroke thrombectomy for patients with large ischemic core:a review[J].JAMA Neurol,2024,81(10):1085-1093. [2] Arkelius K,Wendt TS,Andersson H,et al.LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke[J].Circ Res,2024,134(8):954-969. [3] Li XH,Yin FT,Zhou XH,et al.The signaling pathways and targets of natural compounds from traditional Chinese medicine in treating ischemic stroke[J].Molecules,2022,27(10):3099-3119. [4] Hong KS,Bang OY,Park JH,et al.Moderate-intensity rosuvastatin plus ezetimibe versus high-Intensity rosuvastatin for target low-density lipoprotein cholesterol goal achievement in patients with recent ischemic stroke:a randomized controlled trial[J].Stroke,2023,25(2):242-250. [5] Chen Y,Li J,Dang C,et al.Impact of stroke center certification on rt-PA thrombolysis after acute ischemic stroke in South China from 2015 to 2020[J].Int Stroke,2022,17(5):559-565. [6] 季一飞,余静梅.不同TOAST分型急性缺血性脑卒中诊疗指南及专家共识解读[J].西部医学,2022,34(11):1565-1570. [7] Lim SH,Guek TY,Woon FP,et al.National institutes of health stroke scale:comparison of original and modified versions for singapore culture[J].Singapore Med,2023,64(9):563-566. [8] Zheng K,Lin L,Jiang W,et al.Single-cell RNA-seq reveals the transcriptional landscape in ischemic stroke[J].Cereb Blood Flow Metab,2022,42(1):56-73. [9] 郑蕾,赵书志,刘敏,等.阿替普酶注射剂联合瑞舒伐他汀钙片治疗急性脑梗死的疗效及对神经功能的影响[J].中国医师杂志,2024,26(11):1719-1722. [10] 徐先结,朱天胜,孙林丽.小剂量rt-PA联合阿加曲班治疗急性脑梗死的疗效及对脑组织影像学指标的影响[J].中国实用神经疾病杂志,2023,26(9):1126-1130. [11] 王立敏,吴慧君,王建平,等.低剂量rt-PA静脉溶栓联合双重抗血小板聚集治疗频发高危短暂性脑缺血发作效果及近期预后、安全性分析[J].解放军医药杂志,2022,34(5):69-71. [12] 洪波,谷亚伟,王利军,等.小剂量rt-PA静脉溶栓联合依达拉奉右莰醇治疗高龄中重度急性缺血性脑卒中的时机研究[J].中国慢性病预防与控制,2024,32(7):514-517. [13] 董辉,彭鹏,郭璇,等.心房颤动相关急性缺血性卒中静脉溶栓中阿替普酶用药剂量对疗效的影响[J].中国临床医生杂志,2024,52(10):1187-1189.
2025, Vol. 31 
冀公网安备13080202000786号